LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sensor Array System Detects Cancer Types

By LabMedica International staff writers
Posted on 01 Oct 2012
Print article
Image: Gold nanoparticles (at left) with green fluorescent protein (GFP) “smell” different cancer types in much the same way our noses identify and remember different odors. At right, the distinct protein levels in a cancer interact with the particle to generate patterns used to identify cancer type (Photo courtesy of the University of Massachusetts).
Image: Gold nanoparticles (at left) with green fluorescent protein (GFP) “smell” different cancer types in much the same way our noses identify and remember different odors. At right, the distinct protein levels in a cancer interact with the particle to generate patterns used to identify cancer type (Photo courtesy of the University of Massachusetts).
A rapid, sensitive way to detect microscopic levels of many different metastatic cell types in living tissue has been developed.

A sensor array of gold nanoparticle sensors plus green fluorescent protein (GFP) that activates in response to patterns in the proteins found in cancer cells within minutes, assigning a unique signature to each cancer.

Chemists at the University of Massachusetts Amherst (MA, USA) used a preclinical non-small-cell lung cancer-metastasis model in mice to develop the system. The new work builds an earlier development of a "chemical nose" array of nanoparticles and polymers able to differentiate between normal cells and cancerous ones.

For this work, the scientists took healthy tissue and mouse tumor samples and trained the nanoparticle-GFP sensor array to recognize them and the GFP to fluoresce in the presence of metastatic tissue. Metastases are differentiated from healthy tissue in a matter of minutes, providing a rapid and very general means of detecting and identifying cancer and potentially other diseases using minimally invasive microbiopsies.

In addition to the high sensitivity, the sensor is able to differentiate between low (parental) and high (bone, adrenal, and ovary) metastases, as well as between site-specific cells such as breast, liver, lung and prostate cancers. Until now, the standard method for precisely identifying cancer cells used a biological receptor approach, a protein binding to a cancer cell wall. Its major drawback is that one must know the appropriate receptor beforehand. Array-based sensing approaches discriminate between analytes based on their overall signatures and are emerging as a potential alternative for point-of-care diagnosis.

The authors concluded that the sensor created a distinct fingerprint pattern for the normal and metastatic tumor tissues. Moreover, this array-based approach is unbiased, precluding the requirement of a priori knowledge of the disease biomarkers. Taken together, these studies demonstrate the utility of this sensor for creating fingerprints of cells and tissues in different states and present a general platform for rapid screening amenable to fine needle-aspiration samples. Overall, the authors concluded that this array-based sensing strategy presents the prospect of unbiased phenotype screening of tissue states arising from genetic variations and differentiation state. The study was published on August 26, 2012, in the journal American Chemical Society Nano (ACS Nano).

Related Links:
University of Massachusetts Amherst



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.